An estimated 1 billion+ people worldwide suffer from some form of central nervous system (CNS) disease. While the need is great, progress to better understand and treat CNS disorders has been slow, and at times, disappointing.
Numerous drug treatments for debilitating diseases such as Alzheimer’s and Parkinson’s have made it to mid- and late-stage clinical trials only to fall short in the end of meeting the needed safety and efficacy measures to secure approval. And R&D spending in CNS medical treatments, including mental health, continues to lag behind investment in other diseases. As our population ages, the percentage of those suffering from neurological diseases will continue to grow. It’s imperative that we continue to invest in research to discover new treatments and improve and extend the quality of life of those inflicted.
Fortunately, the future of CNS research looks brighter – with new breakthroughs in R&D and the advancement of new digital ePRO technologies such as patient wearables, sensors and devices to help with measurement and data collection. As we enter this new era, it’s essential that you partner with a CRO that understands the challenges – old and new –and has the expertise to operationalize and de-risk your clinical trial successfully.